Lifespan Rhode Island Hospital
Providence, RI
Accepting patients
LYT-200
A Phase 1 Open-label, Multi-center Study of the Safety, Pharmacokinetics (PK), and Anti-tumor Activity of LYT- 200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)
- Monoclonal Antibody
- Galectin-9 Protein
- Phase 1
- Has results
Accepting patients
PedAL Screening
Pediatric Acute Leukemia (PedAL) Screening Trial - Developing New Therapies for Relapsed Leukemias
- Phase 1/2
Accepting patients
MyeloMATCH Master Protocol
Master Screening and Reassessment Protocol (MSRP) for the NCI MyeloMATCH Clinical Trials
- Genetic Sequencing
- Phase 2